普罗托帕纳克萨迪通过调节PTX3/MAPK/ERK1/2通路来改善狼性炎
Zhenyuan Li1, Hailin Gan1, Kai Ji1
1School of Pharmacy, Key Laboratory of Molecular Pharmacology and Drug Evaluation (Yantai University), Ministry of Education, Collaborative Innovation Center of Advanced Drug Delivery System and Biotech Drugs in Universities of Shandong, Yantai University, No. 32 Qingquan Road, Laishan District, Yantai, 264005, Shandong, People's Republic of China.
Journal of natural medicines
|March 3, 2024
概括
潘特拉辛3 (PTX3) 通过促进细胞增殖,驱动狼性炎 (LN). 化合物Protopanaxadiol (PPD) 通过抑制PTX3通路在治疗LN方面表现有前途.
科学领域:
- 腎臟病學 (nephrology) 是一種醫學專業.
- 免疫学 免疫学 免疫学
- 药理学 药理学是指药理学的学科.
背景情况:
- 狼性炎 (LN) 是系统性红斑狼 (SLE) 的严重并发症.
- 在LN患者中,Pentraxin 3 (PTX3) 含量升高,与疾病严重程度相关.
- 中细胞 (MC) 增殖是LN的一个关键病理特征.
研究的目的:
- 研究PTX3在LN中MC增殖中的作用.
- 评估LN中Protopanaxadiol (PPD) 的治疗潜力.
- 阐明LN中PPD作用的机制.
主要方法:
- 从LN患者和小鼠的脏组织中评估PTX3表达.
- 使用了体外细胞培养和体内小鼠模型 (MRL/lpr小鼠).
- 分析了PPD对MC增殖,蛋白尿和MAPK/ERK1/2通路的影响.
主要成果:
- 在LN脏中观察到PTX3过度表达,与蛋白尿和PCNA相关.
- 高水平的PTX3促进了MC的扩散,MAPK/ERK1/2的激活和HIF-1α的表达.
- PPD治疗降低了MC增殖,改善了MRL/lpr小鼠的蛋白尿,并抑制了PTX3/MAPK/ERK1/2通路.
结论:
- PTX3在MC增殖和LN病原发生方面发挥着重要作用.
- 通过调节PTX3/MAPK/ERK1/2通路,PPD证明了LN的治疗潜力.
- PTX3是治疗狼性炎的潜在治疗标.
更多相关视频
相关概念视频
01:20The JAK-STAT Signaling Pathway
8.9K
Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as SH2...
8.9K
01:22PI3K/mTOR/AKT Signaling Pathway
3.6K
The mammalian target of rapamycin (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1 (mTORC1) and mTOR complex 2 (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast, mTORC2 consists of a...
3.6K
01:07MAPK Signaling Cascades
5.5K
Mitogen-activated protein kinase, or MAPK pathway, activates three sequential kinases to regulate cellular responses such as proliferation, differentiation, survival, and apoptosis. The canonical MAPK pathway starts with a mitogen or growth factor binding to an RTK. The activated RTKs stimulate Ras, which recruits Raf or MAP3 Kinase (MAPKKK), the first kinase of the MAPK signaling cascade. Raf further phosphorylates and activates MEK or MAP2 Kinases (MAPKK), which in turn phosphorylates MAP...
5.5K
01:19Interactions Between Signaling Pathways
6.3K
Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.3K
01:18Treatment for Pulmonary Arterial Hypertension: Endothelin Receptor Antagonists
165
Endothelins (ETs) are potent vasoactive peptides critical in the human body's various physiological and pathological processes. One of the most promising therapeutic strategies for treating pulmonary arterial hypertension (PAH) involves counteracting the effects of these endothelins using a class of drugs known as endothelin receptor antagonists.
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
ETs are synthesized through a complex sequence of enzymatic steps, primarily involving an enzyme referred to as endothelin-converting enzyme...
165
01:19Antiasthma Drugs: Leukotriene Modifiers
298
Leukotriene modifiers, or cysteinyl leukotriene receptor antagonists, are medications used to manage chronic asthma. These agents target specific inflammatory mediators produced during arachidonic acid metabolism, an essential process in generating inflammation in the body.
Leukotriene modifiers work through two distinct mechanisms:
Leukotriene modifiers work through two distinct mechanisms:
298